Work

Capivasertib-Induced Diabetic Ketoacidosis in a Non-diabetic Patient With Metastatic Prostate Cancer With Bone Involvement: A Case Report of a Rare but Serious Metabolic Complication

Year: 2025

Type: article

Abstract: Capivasertib, a protein kinase B (AKT) inhibitor manufactured by AstraZeneca pharmaceutical and used in the treatment of various malignancies, has been implicated in cases of drug-induced diabetic ketoacidosis (DKA). We present a case of capivasertib-induced DKA in a patient with no prior history of diabetes, highlighting the metabolic complications associated with this targeted therapy. The proposed mechanism involves AKT inhibition leading to impaired insulin signaling, reduced glucose uptake, and increased lipolysis, ultimately resulting in ketogenesis. This case underscores the need for vigilant glucose monitoring in patients receiving capivasertib, especially those with predisposing risk factors for insulin resistance or pancreatic dysfunction.

Source: Cureus

DOI: 10.7759/cureus.81513

Authors: Bola Habeb, Otto Valdes, Sandy Khair, Gurmanpreet Sidhu, Matthew Fowler

Institutions: University of Florida, Sacred Heart Hospital, Sacred Heart Health System, Cairo University

Language: English

Topic: PI3K/AKT/mTOR signaling in cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: diamond

OpenAlex ID: W4409002674

FWCI: 1.529

Cites: 7

Cited by: 6

Related to: 10